Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 58.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 144,942 shares of the company's stock after buying an additional 53,726 shares during the period. Graham Capital Management L.P. owned about 0.27% of Fulcrum Therapeutics worth $681,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of FULC. Bank of New York Mellon Corp boosted its stake in Fulcrum Therapeutics by 2.3% during the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock valued at $667,000 after purchasing an additional 3,126 shares during the period. American Century Companies Inc. boosted its stake in Fulcrum Therapeutics by 5.9% during the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after purchasing an additional 6,770 shares during the period. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics during the 4th quarter valued at about $38,000. Wells Fargo & Company MN boosted its stake in Fulcrum Therapeutics by 34.4% during the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after purchasing an additional 8,761 shares during the period. Finally, Intech Investment Management LLC boosted its stake in Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after purchasing an additional 13,057 shares during the period. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Trading Down 2.8%

Shares of NASDAQ:FULC opened at $5.63 on Thursday. The company has a 50 day moving average of $3.53 and a 200-day moving average of $3.75. The firm has a market cap of $303.90 million, a P/E ratio of -18.16 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. Equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $6.67.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.